It is worth noting that these safety issues stemmed mainly from the use of tofacitinib (a pan JAKi) in a population already enriched for cardiovascular diseases (RA patients) and were not confirmed in clinical trials of selective JAK1 inhibitors in AD [76,77]. The gene discussed is JAK1; the disease is Alzheimer disease.